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S U M M A R Y
B A C K G R O U N D : Pulmonary rehabilitation (PR) is a
highly effective non-pharmacological treatment for
patients with chronic respiratory diseases.
O B J E C T I V E : To synthesise the evidence for PR practice
and efficacy in sub-Saharan Africa.
M E T H O D S : We searched in PubMed and Scopus for
relevant studies and scanned reference lists of relevant
studies from these databases for additional studies.
Articles meeting the inclusion criteria were included.
Pre-determined data were extracted independently by
two reviewers. A narrative synthesis approach was used
in the interpretation of findings.
R E S U LT S : Six studies were included, totalling 275
participants. Indications for PR were chronic obstructive
pulmonary disease, asthma, pulmonary tuberculosis and
post-tuberculosis lung disease. Programmes ran for 6–12
weeks, universally incorporated exercise, and variously
used home-based and hospital-based delivery models.
All were interventional studies, of which two were
randomised controlled trials, and primarily reported
pulmonary function and exercise tolerance endpoints.
Evidence for individualising the exercise regimen was
available in three studies.
C O N C L U S I O N S : There is limited evidence on PR design
and efficacy in sub-Saharan Africa, but available data
support its use in a variety of chronic respiratory
conditions. Future studies should report core outcome sets
and their individualised exercise and education regimens.
K E Y W O R D S : pulmonary rehabilitation; chronic respi-
ratory diseases; sub-Saharan Africa; systematic review
CHRONIC RESPIRATORY DISEASES (CRDs) are a
major and increasingly important global health issue;
chronic obstructive pulmonary disease (COPD) and
asthma are the most common among these,1 with
combined annual death rates of approximately 3.15
million.2,3 COPD is increasing in incidence, with age-
standardised mortality being highest in low- and
middle-income countries (LMICs), particularly South
Asia and sub-Saharan Africa (SSA).4,5 Known risk
factors for CRDs include smoking, outdoor air
pollution, household smoke exposure, occupational
dust exposure, ozone and secondhand smoke.6
Pulmonary tuberculosis (PTB) can also lead to
irreversible lung damage which is most frequently
radiologically apparent as bronchiectasis, fibrosis and
cavitation.6,7 Progressive loss of lung function is
associated with long-term respiratory symptoms and
clinical presentation as CRDs, including COPD,
bronchiectasis and aspergillosis.6 These conditions
can jointly be referred to as post-TB chronic lung
disorders (p-TBLD).8 As TB remains one of the top 10
causes of mortality worldwide, with an estimated
10.4 million new cases and 1.3 million deaths in
2016, the problem of p-TBLD is likely to be
substantial but is poorly measured.6
CRDs can lead to significant chronic morbidity and
loss of economic productivity, which burden patients,
families and health systems alike. For conditions such
as COPD, pharmacotherapy such as bronchodilators
is currently the mainstay of the treatment. However,
none of the drugs currently available for COPD can
reduce the progressive decline in lung function which
is the hallmark of this disease.9 In addition, drugs for
CRDs can be less available and affordable, especially
in low-income settings, including SSA, where the
availability and affordability of medicines and
diagnostics recommended for the management of
asthma and COPD is a big challenge.10
Fortunately, the rational use of pharmacotherapy
for CRDs could be complemented by non-pharma-
cological treatments. For COPD, pulmonary rehabil-
itation (PR) is well established as a highly effective
intervention that improves symptoms, quality of life
and survival11, and a recent trial has shown a
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substantial reduction in the risk of readmission in
patients who undertake PR immediately after admis-
sions for COPD.12 Recent evidence also supports PR
for other CRDs, including p-TBLD, asthma, and
interstitial (fibrotic) lung disease (ILD).13 In addition,
while there is still a cost in providing it, PR is
relatively more cost-effective than the pharmacother-
apy for CRDs, as it may be delivered using existing
local staff with minimal equipment. It would thus
require little investment and be sustainable and
scalable in resource-limited settings such as SSA.14
PR is a comprehensive package of interventions,
which can include exercise training, education and
behaviour management.15 Exercise training is a core
component which should be prioritised;16 however,
this may require the modification of traditional
training paradigms, and the need to take into
consideration patient strength and endurance.17 It
has been suggested that PR is now sufficiently
understood to obviate further randomized trials in
high-income countries (HICs).18 However, given that
the design and delivery of PR programmes need to be
individualised to patient groups and context,19 high-
quality data are needed outside HICs.
While the need for PR in SSA is clear, there is
currently no systematic review that has investigated
the research evidence for its practice and effectiveness
in the region. This study is aimed to close this
research gap. Using the PICOS (participants, inter-
ventions, comparisons, outcomes and study design)
approach, we systemically reviewed randomised
controlled trials (RCTs) and non-RCTs to answer
the following questions: 1) In which CRDs has PR
been tested in SSA? 2) What designs and modes of
delivery have been used in PR programmes tested in
people with CRDs in SSA? 3) What is the evidence for
individualising the exercise regimens of the PR
programmes tested in people with CRDs in SSA? 4)
What is the effectiveness of PR in people with CRDs
in SSA?
METHODS
A protocol for this review was registered in the
International Prospective Register of Ongoing Sys-
tematic Reviews (PROSPERO)20 on 1 July 2019
(registration number: CRD42019128929). The con-
duct and reporting of the review were guided by the
Preferred Reporting Items for Systematic Reviews
and Meta-Analyses Protocol (PRISMA-P).21,22 Ethics
approval was not required, as only publicly available
data were used.
Study eligibility criteria and identification
JR and FB independently determined eligibility, and
discrepancies were resolved by consensus. With
reference to the same PICOS approach that informed
our review questions, our eligibility criteria were as
follows: participants with CRDs, attending a PR
programme. The comparison or control domain was
not necessary since additional RCTs comparing PR
and conventional care in CRDs are not warranted as
there is now enough evidence on the superiority of
PR.18 We therefore included both RCTs and non-
RCTs. In the absence of standardised PR core
outcomes, we captured the broadest range of
outcomes possible, including symptoms, functional
limitations, spirometry, and quality of life.
We selected peer-reviewed articles of studies
conducted within SSA between 1997 and 2019. The
start year (1997) was chosen to coincide with the
publication of the first Pulmonary Rehabilitation
Evidence-Based Guidelines.23 Articles must have been
accessible in full text in English (or available
translation) and describe a study on PR for a defined
respiratory disease or syndrome. The searches were
performed in April 2019, using keywords and MeSH
terms in PubMed and Scopus (see Supplementary
Table S1 for search terms used in PubMed); reference
lists were also scanned for relevant secondary
references.
Data extraction, synthesis and analysis
Data were independently extracted by two reviewers
(FB and CF) using a data extraction form which was
based on our pre-review of identified manuscripts,
with consensus-resolution of disagreement. The
following data were sought and either coded or
maintained in narrative form: study characteristics
(country, year of publication and design), participant
characteristics (sample size, condition and mean age),
intervention characteristics (setting of delivery, dura-
tion of session and programme, frequency, compo-
nents, team composition and evidence for
individualising the exercise regimen), endpoints
(primary and secondary) and summary measures of
effect. We extracted all reported outcomes and
synthesised and analysed the extracted data using a
narrative description and tabular summary of key
characteristics of the studies.
Assessment of reporting and methodological quality
We employed the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE)
checklist,24 and assessed potential for bias using the
Newcastle–Ottawa Scale (NOS)25 for non-rando-
mised cohort studies. For randomised controlled
studies, we employed the 2017 Consolidated Stan-
dards of Reporting Trials (CONSORT) checklist of
information to include when reporting a RCT
assessing non-pharmacological treatments (NPTs)26
(for 2-arm parallel-group trials) and a CONSORT
checklist for the reporting of multi-arm parallel-
group RCTs.27 For methodological quality, we
incorporated a revised Cochrane risk-of-bias tool
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Literature search terms identified 86 articles, of
which six met the inclusion criteria (Figure). We
excluded 72 non-relevant articles during title and
abstract review. Of the remaining 14 articles, we
further excluded one duplicate,30 one with abstract
only and no author contact details,31 one non-
research guideline32 and five that did not meet
inclusion criteria.33–37
Study characteristics
Of the six finally included, three studies were
conducted in South Africa,38–40 two in Uganda41,42
and one in Nigeria,43 and all were published between
2010 and 2018. The studies were focused on the
feasibility and acceptability of PR programmes. All 6
were experimental or intervention studies, with 2
being RCTs and 4 being pre-post (before-and-after)
non-RCTs (Table).
Participant characteristics
A total of 275 participants were represented, all aged
18 years. Of these, COPD was the indication for
inclusion in 59 participants across three stud-
ies.38,42,43 A further 88 participants had asthma
within a single study,40 61 participants had p-TBLD
in the two Uganda studies41,42 and 67 participants
were included in a separate study on PTB during anti-
tuberculous treatment39 (Table).
Interventions
The PR programmes used were based either in
referral-level hospitals (n ¼ 3) or at participants’
homes (n ¼ 3). Their durations ranged from 6 to 12
weeks, with variations in composition as follows:
exercise, education, nutrition, self-management ac-
tivities and psychosocial support. The staff who
delivered and supervised the programmes were
variously composed across the studies, with at least
a physiotherapist being present in all programmes to
deliver and supervise the exercise training compo-
nent. The other components of the programmes, such
as education, were delivered and supervised by
various professionals, including physicians, nurses,
physiotherapists, counsellor, home-based caregivers,
students (medical, physiotherapy and nutrition),
assistant researchers (with unspecified expertise or
profession) or a qualified practitioner in exercise
Figure Flow chart of the study selection, adapted from the 2009 PRISMA Group flow diagram.
PRISMA¼ Preferred Reporting Items for Systematic Reviews and Meta-Analyses.


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Pulmonary rehabilitation in sub-Saharan Africa 995
therapy and rehabilitation. More detailed informa-
tion about each study is shown in the Table.
Methodological quality
A standard NOS criterion for what constitutes a high-
quality study has not yet been universally established,
but we considered scores 7 to reflect high quality.44
Based on this criterion, all four non-RCTs were found
to be at high risk of bias (score  5). The issues
included inadequate and/or lack of information on
the three domains (selection, comparability, and
outcome) on which quality assessment was based.
Inadequate and/or lack of information in important
areas were also an issue in the RCTs. Detailed results
from the methodological quality assessment of all
studies are given in Supplementary Table S2.
Exercise individualisation and education
Evidence for individualising the exercise regimens of
PR programmes was available in three studies,40–42
including the evidence for progression of exercise
training loads. For example:
The exercise regime was individually prescribed,
monitored, and increased as the programme pro-
gressed. . .41
The intervention was performed in groups, but the
exercise training was individually prescribed and
intensified as the programme progressed.42
Individual age predicted maximum heart rate
(HRmax) was utilised. . . to develop a suitable pro-
gramme for all subjects without the need for
expensive equipment. . .40
The remaining three studies had no explicit
evidence of regimen individualisation. Details on
other programme components, including education
and self-management aspects, were very limited
(either completely missing or inadequate).
Effectiveness
The Table shows the effects of PR programmes.
Multiple primary outcomes were the norm in all the
studies reviewed, some of which were inconsistently
used, which led to the reporting various results,
including physical, economic, and psychosocial ef-
fects, and self-esteem, health literacy, exercise toler-
ance, pulmonary function and quality of life.
Pulmonary function and exercise tolerance effects
were predominantly assessed and reported. Forced
expiratory volume in 1 sec (FEV1) and forced
expiratory volume (FVC) were common outcome
measures for pulmonary function, while the 6-min
walk test (6MWT) and the incremental shuttle walk
test (ISWT) were used as outcome measures for
exercise tolerance. Pulmonary function was reported
in 5 studies,38–41,43 of which 3 (including the 2
RCTs37,38) demonstrated improvement after the
programme,38–40 1 suggested a non-significant but
potentially clinically important increase,41 and 1
showed no significant change.43 Exercise tolerance
was reported in 4 studies,38,39,41,43 of which 1
reported significant improvement,43 1 reported a
non-significant but potentially clinically important
increase,41 and 2 showed no significant change38,39
(including an RCT39). Dyspnoea, as the most
frequently reported symptom in CRD,45 was assessed
in four studies.38,39,41,43 Of these, 2 reported signif-
icant improvements (including an RCT39),38,39 1
reported a non-significant but potentially clinically
important difference,41 and 1 showed no significant
change.43
DISCUSSION
We found evidence of clinically significant improve-
ments in symptoms and lung function in patients
receiving PR for various CRDs in SSA. However, data
were limited and only three countries were represent-
ed. Studies predominantly examined participants
with COPD (three out of the six studies). While the
evidence base for PR outside of Africa is dominated
by this patient group, recent evidence suggests that
similar benefits could be gained in other CRDs,
including interstitial lung disease, bronchiectasis,
asthma, cystic fibrosis, lung transplantation, lung
cancer and pulmonary hypertension.15,46,47 For
example, a new study has shown that patients with
bronchiectasis benefit from PR to broadly the same
extent as patients with COPD.48 PR is also clearly
indicated in the management of patients with p-
TBLD,15,49 which is infrequently found in high-
income countries, but extremely common in TB-
endemic regions,6 particularly LMICs.50 It is reported
that, in these settings, TB increases the odds of p-
TBLD by more than threefold on average.6
PR can be home- or hospital-/centre-based;11 each
was equally represented in this systematic review.
Although it is recognised that hospital-/centre-based
programmes are a standard mode of PR delivery,51
both modes were effective in various study outcomes
of interest in this systematic review. In a multicentre
RCT,52 home-based PR was found to be a useful,
equivalent alternative to hospital-based PR in pa-
tients with COPD. In addition, another recent study,
which aimed to compare the cost-effectiveness and
cost-utility of home and centre-based PR for adults
with stable COPD, concluded that home-based PR
provided a cost-effective alternative model for people
with COPD who cannot access traditional centre-
based programmes.53 However, to date, home-based
PR has still not been widely adopted into clinical
practice, possibly because a sound economic model
has not been developed.17
In line with recommendations,54 each PR pro-
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gramme ran for at least 6 weeks and focussed on
exercise training, which seems reasonable, as exercise
is a component with the strongest level of evidence for
benefit.16 However, the health gains attributable to a
broader package are important and may be under-
represented in the existing African literature. In
addition, to optimise the physical and physiological
benefits, it is necessary to individualise exercise
training for each patient, including exercise intensi-
ty.55 In this systematic review, there was no evidence
for individualising the PR exercise regimens in three
studies, which made it difficult to assess the quality of
these programmes. Moreover, the issues of method-
ological quality may limit the validity of the study
results when using these as a basis for recommending
PR with absolute certainty in the management of
CRDs in SSA.
There was variable reporting of outcomes of
interest, of which pulmonary function and exercise
tolerance indices predominated. Studies in our review
noted improvements in lung function which might
not be typical of the broader literature. This raises the
possibility that, perhaps due to limited access to
pharmacological therapy, patients in SSA may benefit
differently from those for whom prior pharmacother-
apy was optimal. We note that the choice of reported
metrics was also variable, leading to heterogeneity,
which limits the potential for meta-analysis or a
broader assessment.56,57 Our review would support
the suggestion of a consistently implemented ‘‘core
outcome set’’.58,59 This could reduce outcome report-
ing bias and broaden the relevance to different
stakeholders, including patients, healthcare workers
and those overseeing the wider healthcare system.60
In this systematic review, both exercise tolerance and
dyspnoea were outcomes in four of six stud-
ies;38,39,41,43 these are well-recognised and stakehold-
er-valued positive PR outcomes in other settings.61
Selection of core outcomes should include reaching a
consensus on the key measures which best represent
them.
Our systematic review used a broad search strategy
to identify relevant evidence for PR in SSA and
rigorous implementation of PRISMA guidelines.
However, only studies published in English were
included. This may have limited our sample, but we
found no examples of this during article screening.
The small number of studies, their heterogeneity and
the lack of consistent outcome variables did not allow
meta-analysis.
CONCLUSIONS
Despite limitations, all the included studies in this
review suggest that extending PR programmes in SSA
could be beneficial to patients. Efforts should be
made to individualise the exercise regimens of PR
programmes in the region. Larger studies with high
methodological quality that employ consistent out-
come variables are warranted to allow careful meta-
analysis of both effectiveness and cost-effectiveness.
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R É S U M É
C O N T E X T E : La rééducation pulmonaire (PR) est un
traitement non médicamenteux très efficace pour les
patients atteints de maladies respiratoires chroniques.
O B J E C T I F : Synthétiser les preuves de pratique et
d’efficacité de la PR en Afrique sub-saharienne.
M É T H O D E : Nous avons recherché sur PubMed et
Scopus des études pertinentes ainsi que des listes de
références scannées d’études supplémentaires à partir de
ces bases de données. Les articles répondant aux critères
ont été inclus. Des données prédéterminées ont été
extraites indépendamment par deux réviseurs. Une
approche par synthèse narrative a été utilisée pour
l’interprétation des résultats.
R É S U LTAT S : Six études ont été incluses, pour un total
de 275 participants. Les indications de PR ont été les
maladies pulmonaires chroniques obstructives, l’asthme,
la tuberculose pulmonaire et les pathologies
pulmonaires post-tuberculose. Les programmes de
rééducation ont fonctionné pendant 6–12 semaines,
ont tous incorporé de l’exercice physique et ont été
réalisés soit à domicile soit en hôpital. Toutes les études
ont été des interventions et deux ont été des essais
randomisés contrôlés et ont principalement rapporté les
paramètres de la fonction pulmonaire et de la tolérance à
l’exercice. Des éléments d’individualisation du
programme d’exercice physique ont été disponibles
dans trois études.
C O N C L U S I O N : Il y a peu d’information relative à la
conception et à l’efficacité de la PR en Afrique sub-
saharienne, mais les données disponibles sont en faveur
de son utilisation dans un ensemble de pathologies
respiratoires chroniques. Les études futures devraient
rapporter les principaux résultats obtenus et leurs
protocoles individualisés d’exercice et d’éducation.
R E S U M E N
M A R C O D E R E F E R E N C I A: La rehabilitación respiratoria
(PR) es un tratamiento no farmacológico muy eficaz para
los pacientes con enfermedades pulmonares crónicas.
O B J E T I V O: Sintetizar la evidencia sobre la práctica y la
eficacia de la PR en África subsahariana.
M É T O D O: Se realizó una búsqueda de artı́culos
pertinentes en las bases de datos PubMed y Scopus y se
examinaron las listas de referencias de los artı́culos
escogidos para encontrar otros estudios. Se incluyeron
los artı́culos que cumplı́an los criterios de inclusión. Dos
revisores extrajeron de manera independiente los datos
predeterminados. Los hallazgos se interpretaron
mediante una estrategia de sı́ntesis narrativa.
R E S U LTA D O S: Se incluyeron seis estudios con un total
de 275 participantes. Las indicaciones de la PR eran
enfermedad pulmonar obstructiva crónica, asma,
tuberculosis pulmonar y enfermedad pulmonar
postuberculosis. Los programas duraban de 6–12
semanas, todos comportaban ejercicios y utilizaban
diversamente un modelo de ejecución en los hogares o
en los hospitales. Todos los estudios eran
intervencionistas y dos de ellos eran ensayos
aleatorizados y notificaban como principales criterios
de evaluación, esencialmente la función respiratoria y la
tolerancia al ejercicio. Tres estudios contenı́an
información sobre la individualización del esquema de
ejercicios.
C O N C L U S I Ó N: La evidencia sobre el diseño y la eficacia
de la PR en África subsahariana es limitada, pero se
cuenta con datos que respaldan su utilización en una
diversidad de afecciones respiratorias crónicas. Serı́an
útiles estudios futuros que comuniquen conjuntos
básicos de criterios de evaluación, sus esquemas de
ejercicios individualizados y los programas educativos.
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